NCT01452776View on ClinicalTrials.gov

Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis

PHASE3CompletedINTERVENTIONAL

Enrollment

305

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions

Erosive Esophagitis

Interventions

DRUG

TAK-438

TAK-438 10 mg, tablets, orally, once daily for up to 52 weeks.

DRUG

TAK-438

TAK-438 20 mg, tablets, orally, once daily for up to 52 weeks.

Trial Locations (32)

Unknown

Nagoya

Abiko-shi

Fukuoka

Itoshima-shi

Kurume-shi

Onga-gun

Gifu

Annaka-shi

Aki-gun

Hiroshima

Sapporo

Amagasaki-shi

Kobe

Takarazuka-shi

Sakaide-shi

Yokohama

Kochi

Susaki-shi

Kumamoto

Kyoto

Nagasaki

Ōita

Okayama

Fuziidera-shi

Shizuoka

Otawara-shi

Chiyoda-ku

Chuo-ku

Nakano-ku

Ōta-ku

Setagaya-ku

Yamagata

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY

NCT01452776 - Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis | Biotech Hunter | Biotech Hunter